{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:55:43Z","timestamp":1790589343781,"version":"4.1.0"},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2026-0173_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Reliable biomarkers may allow early risk stratification for mortality in older adults. Post-translational modification-derived products (PTMDPs), such as homocitrulline, and the tissue accumulation of advanced glycation end products (AGEs), measured by skin autofluorescence, have been suggested as potential biomarkers of adverse outcomes in older and frail individuals. The aim of this study was to assess their association with 3-year mortality following hospitalisation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0173_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We followed a cohort of 250 hospitalised patients over 3\u00a0years. Serum PTMDPs (homocitrulline, carboxymethyllysine, pentosidine, and MG-H1) were measured using liquid chromatography coupled with tandem mass spectrometry, and AGEs were quantified by skin autofluorescence. We examined associations with mortality using bivariable analyses and a multivariable Cox regression model. An exploratory cut-off for homocitrulline was established at the third quartile of its distribution within the study population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0173_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During follow-up, 92 deaths occurred. In bivariable analyses, all biomarkers were associated with mortality. In the multivariable model, homocitrulline levels of &gt;400\u202f\u03bcmol\/mol Lys were significantly associated with mortality (hazard ratio 1.73, 95\u202f% confidence interval 1.06\u20132.82), after adjustment for age, frailty, and comorbidities. The model\u2019s predictive performance, with an area under the curve (AUC) of 0.76, was only slightly affected by the exclusion of homocitrulline (AUC=0.755).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0173_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results indicate that although elevated homocitrulline was independently associated with mortality, its incremental value for risk prediction was modest. Larger studies are needed to further evaluate the clinical utility of PTMDPs, especially homocitrulline, for risk prediction and clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2026-0173","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:26:28Z","timestamp":1782905188000},"page":"2503-2509","source":"Crossref","is-referenced-by-count":0,"title":["Homocitrulline and 3-year mortality in older hospitalised adults: an exploratory study"],"prefix":"10.1515","volume":"64","author":[{"given":"Peter","family":"Noujaim","sequence":"first","affiliation":[{"name":"UR 3797 Ageing, Frailty (VieFra), CHU Reims, Methodological Support Unit , University of Reims Champagne-Ardenne , Reims , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Jaisson","sequence":"additional","affiliation":[{"name":"Extracellular Matrix and Cell Dynamics Unit (MEDyC) UMR 7369 , CNRS, University of Reims Champagne-Ardenne , Reims , France"},{"name":"Department of Biochemistry-Pharmacology-Toxicology , University Hospital of Reims , Reims , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Pierrard","sequence":"additional","affiliation":[{"name":"Oral Medicine Pole , Reims University Hospital , Reims , France"},{"name":"Faculty of Medicine , 206\u00a0\u2013\u00a0University of Reims Champagne-Ardenne , Reims , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Badr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Geriatrics , University Hospital of Reims , Reims , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gillery","sequence":"additional","affiliation":[{"name":"Extracellular Matrix and Cell Dynamics Unit (MEDyC) UMR 7369 , CNRS, University of Reims Champagne-Ardenne , Reims , France"},{"name":"Department of Biochemistry-Pharmacology-Toxicology , University Hospital of Reims , Reims , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4741-1934","authenticated-orcid":false,"given":"Rachid","family":"Mahmoudi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Geriatrics , University Hospital of Reims , Reims , France"},{"name":"UR 3797 Ageing, Frailty (VieFra) , University of Reims Champagne-Ardenne , Reims , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026092809015486177_j_cclm-2026-0173_ref_001","unstructured":"Direction de la recherche, des \u00e9tudes, de l\u2019\u00e9valuation et des statistiques (DREES). Les personnes \u00e2g\u00e9es et leurs ressources. [online]. https:\/\/drees.solidarites-sante.gouv.fr\/sites\/default\/files\/2022-12\/AAS22-Fiche%2011%20-%20Les%20personnes%20%C3%A2g%C3%A9es%20et%20leurs%20ressources.pdf [Accessed 20 June 2024]."},{"key":"2026092809015486177_j_cclm-2026-0173_ref_002","doi-asserted-by":"crossref","unstructured":"Cesari, M, Prince, M, Thiyagarajan, JA, De Carvalho, IA, Bernabei, R, Chan, P, et al.. Frailty: an emerging public health priority. J\u00a0Am Med Dir Assoc 2016;17:188\u201392. https:\/\/doi.org\/10.1016\/j.jamda.2015.12.016.","DOI":"10.1016\/j.jamda.2015.12.016"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_003","doi-asserted-by":"crossref","unstructured":"Romera-Liebana, L, Orfila, F, Segura, JM, Real, J, Fabra, ML, M\u00f6ller, M, et al.. Effects of a primary care-based multifactorial intervention on physical and cognitive function in frail, elderly individuals: a randomized controlled trial. J\u00a0Gerontol A Biol Sci Med Sci 2018;73:1688\u201374. https:\/\/doi.org\/10.1093\/gerona\/glx259.","DOI":"10.1093\/gerona\/glx259"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_004","doi-asserted-by":"crossref","unstructured":"Mahmoudi, R, Jaisson, S, Badr, S, Jaidi, Y, Bertholon, LA, Novella, JL, et al.. Post-translational modification-derived products are associated with frailty status in elderly subjects. Clin Chem Lab Med 2019;57:1153\u201361. https:\/\/doi.org\/10.1515\/cclm-2018-1322.","DOI":"10.1515\/cclm-2018-1322"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_005","doi-asserted-by":"crossref","unstructured":"Gillery, P, Jaisson, S. Usefulness of non-enzymatic post-translational modification derived products (PTMDPs) as biomarkers of chronic diseases. J\u00a0Proteonomics 2013;92:228\u201338. https:\/\/doi.org\/10.1016\/j.jprot.2013.02.015.","DOI":"10.1016\/j.jprot.2013.02.015"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_006","doi-asserted-by":"crossref","unstructured":"Gorisse, L, Jaisson, S, Pietrement, C, Gillery, P. Protein carbamylation: when protein and chronologic ageings meet. Med Sci 2016;32:684\u20136. https:\/\/doi.org\/10.1051\/medsci\/20163208008.","DOI":"10.1051\/medsci\/20163208008"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_007","doi-asserted-by":"crossref","unstructured":"Gorisse, L, Pietrement, C, Vuiblet, V, Schmelzer, CEH, K\u00f6hler, M, Duca, L, et al.. Protein carbamylation is a hallmark of aging. Proc Natl Acad Sci USA 2016;113:1191\u20136. https:\/\/doi.org\/10.1073\/pnas.1517096113.","DOI":"10.1073\/pnas.1517096113"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_008","doi-asserted-by":"crossref","unstructured":"Koeth, RA, Kalantar-Zadeh, K, Wang, Z, Fu, X, Tang, WHW, Hazen, SL. Protein carbamylation predicts mortality in ESRD. J\u00a0Am Soc Nephrol 2013;24:853\u201361. https:\/\/doi.org\/10.1681\/asn.2012030254.","DOI":"10.1681\/ASN.2012030254"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_009","doi-asserted-by":"crossref","unstructured":"Berg, AH, Drechsler, C, Wenger, J, Buccafusca, R, Hod, T, Kalim, S, et al.. Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 2013;5:175ra29. https:\/\/doi.org\/10.1126\/scitranslmed.3005218.","DOI":"10.1126\/scitranslmed.3005218"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_010","doi-asserted-by":"crossref","unstructured":"Drechsler, C, Kalim, S, Wenger, JB, Suntharalingam, P, Hod, T, Thadhani, RI, et al.. Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease. Kidney Int 2015;87:1201\u20138. https:\/\/doi.org\/10.1038\/ki.2014.429.","DOI":"10.1038\/ki.2014.429"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_011","doi-asserted-by":"crossref","unstructured":"Kim, DH, Rockwood, K. Frailty in older adults. N\u00a0Engl J Med 2024;391:538\u201348. https:\/\/doi.org\/10.1056\/nejmra2301292.","DOI":"10.1056\/NEJMra2301292"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_012","doi-asserted-by":"crossref","unstructured":"Fried, LP, Tangen, CM, Walston, J, Newman, AB, Hirsch, C, Gottdiener, J, et al.. Frailty in older adults: evidence for a phenotype. J\u00a0Gerontol A Biol Sci Med Sci 2001;56:M146\u201356. https:\/\/doi.org\/10.1093\/gerona\/56.3.m146.","DOI":"10.1093\/gerona\/56.3.M146"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_013","doi-asserted-by":"crossref","unstructured":"Vellas, B, Guigoz, Y, Garry, PJ, Nourhashemi, F, Bennahum, D, Lauque, S, et al.. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition 1999;15:116\u201322. https:\/\/doi.org\/10.1016\/s0899-9007(98)00171-3.","DOI":"10.1016\/S0899-9007(98)00171-3"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_014","doi-asserted-by":"crossref","unstructured":"Levey, AS, Stevens, LA, Schmid, CH, Zhang, YL, Castro, AF, Feldman, HI, et al.. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_015","doi-asserted-by":"crossref","unstructured":"Awwad, A, Rhee, EP, Grams, M, Choles, HR, Sondheimer, J, He, J, et al.. Comparative CKD risk prediction using homocitrulline and carbamylated albumin: two circulating markers of protein carbamylation. BMC Nephrol 2024;25:185. https:\/\/doi.org\/10.1186\/s12882-024-03619-6.","DOI":"10.1186\/s12882-024-03619-6"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_016","doi-asserted-by":"crossref","unstructured":"Ottosson, F, Smith, E, Fernandez, C, Melander, O. Plasma metabolites associate with all-cause mortality in individuals with type 2 diabetes. Metabolites 2020;10:315. https:\/\/doi.org\/10.3390\/metabo10080315.","DOI":"10.3390\/metabo10080315"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_017","doi-asserted-by":"crossref","unstructured":"Oshitari, T. Advanced glycation end-products and diabetic neuropathy of the retina. Int J Mol Sci 2023;24:2927. https:\/\/doi.org\/10.3390\/ijms24032927.","DOI":"10.3390\/ijms24032927"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_018","doi-asserted-by":"crossref","unstructured":"Zgutka, K, Tkacz, M, Tomasiak, P, Tarnowski, M. A role for advanced glycation end products in molecular ageing. Int J Mol Sci 2023;24:9881. https:\/\/doi.org\/10.3390\/ijms24129881.","DOI":"10.3390\/ijms24129881"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_019","doi-asserted-by":"crossref","unstructured":"Genuth, S, Sun, W, Cleary, P, Sell, DR, Dahms, W, Malone, J, et al.. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005;54:3103\u201311. https:\/\/doi.org\/10.2337\/diabetes.54.11.3103.","DOI":"10.2337\/diabetes.54.11.3103"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_020","doi-asserted-by":"crossref","unstructured":"Smoor, RM, van Dongen, EPA, Verwijmeren, L, Emmelot-Vonk, MH, Vernooij, LM, Cremer, OL, et al.. Advanced glycation end products for preoperative frailty screening in older cardiac surgery patients. J\u00a0Am Geriatr Soc 2023;71:2520\u20139. https:\/\/doi.org\/10.1111\/jgs.18361.","DOI":"10.1111\/jgs.18361"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_021","doi-asserted-by":"crossref","unstructured":"Picca, A, Coelho-Junior, HJ, Calvani, R, Marzetti, E, Vetrano, DL. Biomarkers shared by frailty and sarcopenia in older adults: a systematic review and meta-analysis. Ageing Res Rev 2022;73:101530. https:\/\/doi.org\/10.1016\/j.arr.2021.101530.","DOI":"10.1016\/j.arr.2021.101530"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_022","doi-asserted-by":"crossref","unstructured":"Dalal, M, Ferrucci, L, Sun, K, Beck, J, Fried, LP, Semba, RD. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. J\u00a0Gerontol A Biol Sci Med Sci 2009;64:132\u20137. https:\/\/doi.org\/10.1093\/gerona\/gln018.","DOI":"10.1093\/gerona\/gln018"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_023","doi-asserted-by":"crossref","unstructured":"Ye, L, Liang, R, Liu, X, Li, J, Yue, J, Zhang, X. Frailty and sarcopenia: a bibliometric analysis of their association and potential targets for intervention. Ageing Res Rev 2023;92:102111. https:\/\/doi.org\/10.1016\/j.arr.2023.102111.","DOI":"10.1016\/j.arr.2023.102111"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_024","unstructured":"Roubenoff, R. Sarcopenia: a major modifiable cause of frailty in the elderly. J\u00a0Nutr Health Aging 2000;4:140\u20132."},{"key":"2026092809015486177_j_cclm-2026-0173_ref_025","doi-asserted-by":"crossref","unstructured":"Nygaard, H, Kamper, RS, Ekmann, A, Hansen, SK, Hansen, P, Schultz, M, et al.. Co-occurrence of sarcopenia and frailty in acutely admitted older medical patients: results from the copenhagen PROTECT study. J\u00a0Frailty Aging 2024;13:91\u20137. https:\/\/doi.org\/10.14283\/jfa.2024.23.","DOI":"10.14283\/jfa.2024.23"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_026","unstructured":"Taaffe, DR. Sarcopenia--exercise as a treatment strategy. Aust Fam Physician 2006;35:130\u20134."},{"key":"2026092809015486177_j_cclm-2026-0173_ref_027","unstructured":"Roth, SM, Ferrell, RF, Hurley, BF. Strength training for the prevention and treatment of sarcopenia. J\u00a0Nutr Health Aging 2000;4:143\u201355."},{"key":"2026092809015486177_j_cclm-2026-0173_ref_028","doi-asserted-by":"crossref","unstructured":"Travers, J, Romero-Ortuno, R, Bailey, J, Cooney, MT. Delaying and reversing frailty: a systematic review of primary care interventions. Br J Gen Pract 2019;69:e61\u20139. https:\/\/doi.org\/10.3399\/bjgp18x700241.","DOI":"10.3399\/bjgp18X700241"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_029","doi-asserted-by":"crossref","unstructured":"Takatori, K, Matsumoto, D. Social factors associated with reversing frailty progression in community-dwelling late-stage elderly people: an observational study. PLoS One 2021;16:e0247296. https:\/\/doi.org\/10.1371\/journal.pone.0247296.","DOI":"10.1371\/journal.pone.0247296"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_030","doi-asserted-by":"crossref","unstructured":"Aili, SR, Lo, P, Villanueva, JE, Joshi, Y, Emmanuel, S, Macdonald, PS. Prevention and reversal of frailty in heart failure\u00a0\u2013\u00a0a systematic review. Circ J 2021;86:14\u201322. https:\/\/doi.org\/10.1253\/circj.cj-21-0819.","DOI":"10.1253\/circj.CJ-21-0819"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_031","doi-asserted-by":"crossref","unstructured":"Cristofori, G, Aguado-Ortego, R, G\u00f3mez-Pav\u00f3n, J. The concept and practical management of frailty in neurology. Rev Neurol 2023;76:327\u201336.","DOI":"10.33588\/rn.7610.2023124"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_032","doi-asserted-by":"crossref","unstructured":"Cardoso, AL, Fernandes, A, Aguilar-Pimentel, JA, de Angelis, MH, Guedes, JR, Brito, MA, et al.. Towards frailty biomarkers: candidates from genes and pathways regulated in aging and age-related diseases. Ageing Res Rev 2018;47:214\u201377. https:\/\/doi.org\/10.1016\/j.arr.2018.07.004.","DOI":"10.1016\/j.arr.2018.07.004"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_033","doi-asserted-by":"crossref","unstructured":"Salvioli, S, Basile, MS, Bencivenga, L, Carrino, S, Conte, M, Damanti, S, et al.. Biomarkers of aging in frailty and age-associated disorders: state of the art and future perspective. Ageing Res Rev 2023;91:102044. https:\/\/doi.org\/10.1016\/j.arr.2023.102044.","DOI":"10.1016\/j.arr.2023.102044"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_034","doi-asserted-by":"crossref","unstructured":"Mir, R, Jha, CK, Khullar, N, Maqbool, M, Dabla, PK, Mathur, S, et al.. The role of inflammatory and cytokine biomarkers in the pathogenesis of frailty syndrome. Endocr Metab Immune Disord Drug Targets 2022;22:1357\u201366. https:\/\/doi.org\/10.2174\/1871530322666220304220522.","DOI":"10.2174\/1871530322666220304220522"},{"key":"2026092809015486177_j_cclm-2026-0173_ref_035","doi-asserted-by":"crossref","unstructured":"Delanaye, P, Vart, P, Floege, J, Zoccali, C. Age-adapted versus age-independent eGFR thresholds to diagnose CKD: integrating the debate and charting a balanced path forward. Clin Kidney J 2025;18:sfaf328. https:\/\/doi.org\/10.1093\/ckj\/sfaf328.","DOI":"10.1093\/ckj\/sfaf328"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0173\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:04:00Z","timestamp":1790586240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0173\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,7,9]]},"published-print":{"date-parts":[[2026,10,26]]}},"alternative-id":["10.1515\/cclm-2026-0173"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0173","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}